/DISREGARD RELEASE: NeuroGen/

We are advised by NeuroGen that journalists and other readers should disregard the news release, China’s First CGRP Targeted Therapy to Enter the NRDL: NeuroGen Officially Launches Ajovy® (fremanezumab), Benefiting the First Cohort of Migraine Patients, issued 18-Nov-2026 over PR Newswire. The release has been withdrawn following a change to the issuer’s distribution arrangements.

Subscribe on LinkedIn

PR Newswire is solely responsible for the content of the above news submissions. If there are any violations of laws, violations of the membership terms of this website, or the risk of infringing on the rights of third parties, PR Newswire will be solely responsible for legal and damage compensation. Responsibility has nothing to do with MedicaEx.

Are you in?

Stay up-to-date with the latest Newsletters, free of charge.